BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moaven O, Clark CJ, Russell GB, Votanopoulos KI, Howerton R, Levine EA, Shen P. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. Ann Surg 2020. [PMID: 31913868 DOI: 10.1097/SLA.0000000000003770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Naffouje SA, Sabesan A, Kim DW, Carballido E, Frakes J, Hodul P, Denbo JW, Malafa M, Fleming J, Hoffe S. Adjuvant Chemoradiotherapy in Resected Pancreatic Ductal Adenocarcinoma: Where Does the Benefit Lie? A Nomogram for Risk Stratification and Patient Selection. J Gastrointest Surg 2021. [PMID: 34506031 DOI: 10.1007/s11605-021-05130-x] [Reference Citation Analysis]
2 Shi X, Peng J, Jiang H, Gao Y, Wang W, Zhou F. Impact of Adjuvant Chemoradiotherapy on Survival of Resected Pancreatic Adenocarcinoma Cancer: A Surveillance, Epidemiology and End Results (SEER) Analysis. Front Oncol 2021;11:651671. [PMID: 34277405 DOI: 10.3389/fonc.2021.651671] [Reference Citation Analysis]
3 Tentes AK. Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection. J Gastrointest Oncol 2021;12:S91-8. [PMID: 33968429 DOI: 10.21037/jgo-20-46] [Reference Citation Analysis]